Under the agreement, the two firms aim to discover and validate genetic markers related to drug response and create a diagnostic test to guide therapy. Genaissance will receive license fees as well as payments for genotyping clinical samples. In addition, the company will have certain rights to co-develop and co-commercialize a companion genetic test.
Last month, Genaissance signed a deal with another Japanese pharma firm, Otsuka Pharmaceutical. "We hope to see more such agreements with Japanese companies in the future," said Genaissance CEO Kevin Rakin in a statement.